

ADTC(M) 17/04
Minutes: 47 - 58

NHS GREATER GLASGOW AND CLYDE

**Minutes of a Meeting of the
Area Drugs and Therapeutics Committee
held in the Boardroom, JB Russell House
on Monday, 28 August 2017 at 2.00 p.m.**

P R E S E N T

Dr S Muir (in the Chair)

Mrs J Watt	Mrs Y Semple
Dr J Simpson	Mr R Foot
Dr J Mackenzie	Dr K O'Neill
Dr A Taylor	Ms F Thomson
Dr B MacKinnon	Mrs Margaret Ryan
Mr D Malcolmson	Mrs L Hillan
Dr J Burns	Mr G Gorman
Dr G Forrest	

I N A T T E N D A N C E

Mrs L Russell.....Secretariat Officer
Ms L McCallum.....Observer

ACTION BY

47. CHAIR'S STATEMENT

The Chair reminded Members that papers and proceedings relating to SMC advice were, in some cases, confidential and should not be disclosed before the relevant embargo dates stated in the agenda.

He also reminded Members that they should make relevant declarations of interest in line with Board policy.

Members were advised not to speak with members of the press on ADTC business but to refer such enquiries to the Board press liaison office.

48. APOLOGIES AND WELCOME

Apologies for absence were intimated on behalf of Dr A Seaton, Prof N Lannigan, Prof G McKay, Dr R Hardman, Mrs A Muir, Dr C Harrow, Mr A Crighton and Mrs A Campbell.

The Chair welcomed Mr Douglas Malcolmson, Lead Clinical Pharmacist, and Dr B MacKinnon, Consultant Nephrologist, to the Committee. He also welcomed Ms Lyndsay McCallum who was in attendance to observe proceedings.

49. MINUTES

The minutes of the meeting of the Area Drugs and Therapeutics Committee held on 19 June 2017 were approved as a correct record.

50. MATTERS ARISING

SMC advice re PCSK9 inhibitors

The ADTC wrote to SMC in June regarding some unintended consequences in relation to the wording used to define restrictions for the prescribing of alirocumab and evolocumab. Alternative wording was suggested for consideration in future to encapsulate intended positioning in relation to specialist prescribing. Dr Muir informed members that a formal response was received from Dr Alan MacDonald. SMC recognise the need to be thoughtful in distinguishing between those medicines that should be initiated and supplied from a specialist and those that need initiated on advice of a specialist. SMC Standard Operating Procedures will be updated in light of this.

Members noted the update provided.

51. FORMULARY AND NEW DRUGS SUB-COMMITTEE

(1) Report on SMC Product Assessments

Members were asked to declare any interests specific or non-specific, personal or non-personal, on any of the drugs being discussed on an individual basis.

No declarations of interest were made.

See Appendix 1 for summarised decisions

52. MEDICINES UTILISATION SUB-COMMITTEE

Six Monthly Report

The Committee noted the Medicines Utilisation Sub-Committee 6 monthly report to inform the ADTC of the work of the Sub-Committee.

The key work of the Sub-Committee continues to focus on Guidelines/Protocols, Medicines Utilisation reports, Clinical Effectiveness Projects, GGC Therapeutics Handbook and Medicines Education.

Dr O'Neill reported that 15 guidelines have been reviewed and approved by the Sub Committee over the last 6 months and will be posted within the Electronic Guideline Directory. An appendix has been included in the report to highlight the guidelines reviewed and approved.

Work continues on a number of clinical effectiveness projects by the Clinical Effectiveness Team.

The Therapeutics Handbook and App continue to be updated.

The DOAC FAQ has formed a large part of the Medicines Education workplan. A Medicines Extra Update for Oral NSAIDs has been developed.

The Committee acknowledged the work carried out by the Sub-Committee and briefly discussed how the work could be more widely publicised. The Committee agreed that further consideration should be given on improving the mechanism for sharing key messages.

The Committee acknowledged the 6 monthly report and noted the developments.

53. OTHER ADTC SUB-COMMITTEES

(a) Communications Sub-Committee

GGC Medicines Update

A GGC Medicines Update paper was circulated to the Committee for information. The paper provided detail on Medicines Updates and the benefits of the blog. The team are considering the most effective ways of communicating key messages. The Committee agreed it would be helpful for the Chairs of the Sub-Committees to highlight the key messages at their meetings. Leaders should pass on key messages to junior members of staff.

A GGC Medicines Twitter and Facebook page has been set up which is working well. The Committee noted that having access to the general GGC Twitter/Facebook accounts would allow a bigger reach. Discussions are taking place regarding this.

Mrs Semple informed the Committee that members of the Communications Sub-Committee are available to attend meetings to provide further information. Members of the Sub-Committees are also welcome to join the Communications Sub-Committee which would help broaden membership. The Sub-Committee will continue to explore ways to increase social media presence, for example creating a You Tube channel.

There is an ADTC page on the GGC Medicines website and the minutes of the meetings are held there. Any appropriate content can be shared on the website.

The Committee agreed that the Chairs of the Sub-Committees will take the update paper to their next meeting. It was also noted that volunteers from medical and nursing are required to join the Communications Sub-Committee.

The Committee noted the paper and update provided.

54. ADTC COLLABORATIVE

ADTCC Update

The Committee noted the report submitted for information.

55. NHS SCOTLAND VALPROATE PATIENT SAFETY ALERT

Following the last meeting, Mrs Semple gathered information on how the blog article and recommendations were being used in Greater Glasgow and Clyde. A teleconference was held following dissemination of the paperwork. MHRA developed patient information which was disseminated by Acute services. Mrs Semple is waiting on feedback from specialists. A piece of work will take place within Primary Care.

Mrs Semple will prepare and submit a summary paper to the Committee in due course.

**Mrs
Semple**

56. PRESCRIBING MANAGEMENT GROUP REPORT

Efficiency summits have been held by Acute and Primary Care. Acute feel it would be helpful to hold another summit. Implications for the Formulary will form part of that work.

57. ANY OTHER BUSINESS

The Committee noted that Professor Norman Lannigan has retired. The Chair thanked Professor Lannigan for his valued contribution to the Committee over a number of years and wished him well in his retirement.

58. DATE OF NEXT MEETING

Monday, 23 October 2017 – Boardroom, JB Russell House, Gartnavel Royal Hospital